Evidence map›Paper›PMID 24449580›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2014

A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.

Maureen McMahon, Brian J Skaggs, Jennifer M Grossman, Lori Sahakian, John Fitzgerald, Weng Kee Wong, Elaine V Lourenco, Nagesh Ragavendra, Christina Charles-Schoeman, Alan Gorn and 6 more

Open access · greenAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Vascular damage in systemic lupus erythematosus.Nature reviews. Nephrology · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Maureen McMahonUniversity of California, Los Angeles.
Brian J Skaggs
Jennifer M Grossman
Lori Sahakian
John Fitzgerald
Weng Kee Wong
Elaine V Lourenco
Nagesh Ragavendra
Christina Charles-Schoeman
Alan Gorn
George A Karpouzas
Mihaela B Taylor
Karol E Watson
Michael H Weisman
Daniel J Wallace
Bevra H Hahn
University of California, Los Angeles · USCedars-Sinai Medical Center · USHarbor–UCLA Medical Center · US

Funding

The Role of Monocytes in SLE-related Accelerated AtherosclerosisK01AR059095 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SKAGGS, BRIAN J · 2010 to 2014
$695k
Pro-Inflammatory HDL as a Novel Target for the Indentification of AtherosclerosisK23AR053864 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCMAHON, MAUREEN A · 2007 to 2011
$625k
NIAMS NIH HHS 1K23-AR0-53864-01A1NIAMS NIH HHS K01 AR059095NIAMS NIH HHS K01-AR-059095NIAMS NIH HHS K23 AR053864
6 · The paper itself

Abstract

objectiveAn increased frequency of atherosclerosis (ATH) in systemic lupus erythematosus (SLE) is well-documented but not fully explained by the presence of traditional cardiac risk factors. Several nontraditional biomarkers, including proinflammatory high-density lipoprotein (piHDL) and leptin, have been individually associated with subclinical ATH in SLE. The aim of this study was to examine whether these and other biomarkers can be combined into a risk profile, the Predictors of Risk for Elevated Flares, Damage Progression, and Increased Cardiovascular Disease in Patients with SLE (PREDICTS), that could be used to better predict future progression of ATH.

methodsIn total, 210 patients with SLE and 100 age-matched healthy control subjects (all women) participated in this prospective cohort study. The longitudinal presence of carotid plaque and intima-media thickness (IMT) were measured at baseline and followup (mean ± SD 29.6 ± 9.7 months).

resultsAt followup, carotid plaque was present in 29% of SLE patients. Factors significantly associated with plaque, determined using Salford Predictive Modeling and multivariate analysis, included age ≥48 years (odds ratio [OR] 4.1, P = 0.002), high piHDL function (OR 9.1, P < 0.001), leptin levels ≥34 ng/dl (OR 7.3, P = 0.001), plasma soluble TWEAK levels ≥373 pg/ml (OR 28.8, P = 0.004), and history of diabetes (OR 61.8, P < 0.001). Homocysteine levels ≥12 μmoles/liter were also a predictor. However, no single variable demonstrated an ideal combination of good negative predictive values (NPVs), positive predictive values (PPVs), sensitivity, and specificity. A high-risk PREDICTS profile was defined as ≥3 positive biomarkers or ≥1 positive biomarker plus a history of diabetes; for high-risk SLE patients, the PPV was 64%, NPV was 94%, sensitivity was 89%, and specificity was 79%. In multivariate analysis, SLE patients with the high-risk profile had 28-fold increased odds for the longitudinal presence of plaque (P < 0.001) and increased progression of IMT (P < 0.001).

conclusionA high-risk PREDICTS score confers 28-fold increased odds of the presence of any current, progressive, or acquired carotid plaque, both in patients with SLE and in control subjects, and is significantly associated with higher rates of IMT progression.

Indexed as

AdiponectinAdultAge FactorsApolipoprotein A-IAtherosclerosisBiomarkersCarotid ArteriesCarotid Artery DiseasesCarotid Intima-Media ThicknessCase-Control StudiesCholesterol, HDLCholesterol, LDLCohort StudiesCytokine TWEAKDiabetes ComplicationsDiabetes MellitusAdiponectinApolipoprotein A-IBiomarkersCholesterol, HDLCholesterol, LDLCytokine TWEAKHomocysteineLeptinTNFSF12 protein, humanTumor Necrosis Factors

Identifiers

PMID24449580
PMCPMC4106468
OpenAlexW1907737807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.